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Abbreviations: 
 
CSC: cancer stem cells  
PDAC: pancreatic adenocarcinomas 
hCAP-18/LL-37: human cationic antimicrobial peptide 18/LL-37 
LL-37: leucine leucine 37 
rLL-37: recombinant leucine leucine 37 
TAM: tumour-associated macrophage 
TGF-β1: tumor growth factor-β1 
FPR2: formyl peptide receptor 2 
P2X7R: P2X purinoceptor 7 receptor (P2X7R) 
CAMP: cathelicidin antimicrobial peptide 
CRAMP: cathelicidin-related antimicrobial peptide 
PSC: pancreatic stellate cell 
PDX: patient-derived xenografts 
KPC: K-Ras
+/LSL-G12D
;Trp53
LSL-R172H
;PDX1-Cre 
RT-qPCR: Real-time quantitative polymerase chain reaction 
RSAD2: radical S-adenosyl methionine domain containing 2 
CMPK2: cytidine monophosphate (UMP-CMP) kinase 2 
KRT19: kertain 19 
SIGLEC1: sialic acid binding Ig-like lectin 1 
ORM1: orosomucoid 1 
TMA: tissue microarray 
YM1: chitinase 3-like 3 
F4/80: macrophage (M phi)-specific monoclonal antibody 
CXCR4: C-X-C chemokine receptor type 4 
EMT: epithelial to mesenchymal transition 
GM-CSF: granulocyte-macrophage colony-stimulating factor 
CM: conditioned medium 
OSM: oncostatin M 
VEGF: vascular endothelial growth factor 
VDR: vitamin D receptor 
Alk4: Activin-like 4 
CTCs: circulating tumour cells 
EPCAM: epithelial cell adhesion molecule 
PanIN: pancreatic intraepithelial neoplasia 
OAS: (2'-5') oligo A synthetase 
MX1: nterferon-induced GTP-binding protein 
ISG15: interferon stimulated gene 15 
GEM: gemcitabine 
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ABSTRACT 
Objectives: The tumour stroma/microenvironment not only provides structural support for tumour 
development, but more importantly it provides cues to cancer stem cells (CSC) that regulate their self-
renewal and metastatic potential. This is certainly true for pancreatic adenocarcinomas (PDAC), where 
tumour-associated fibroblasts, pancreatic stellate cells and immune cells create an abundant paracrine 
niche for CSCs via microenvironment-secreted factors. Thus understanding the role that tumour stroma 
cells play in PDAC development and CSCs biology is of utmost importance. 
Design: Microarray analyses, tumour microarray immunohistochemical assays, in vitro co-culture 
experiments, recombinant protein treatment approaches and in vivo intervention studies were performed 
to understand the role that the immuno-modulatory cationic antimicrobial peptide 18/LL-37 (hCAP-
18/LL-37) plays in PDAC biology. 
Results: We found that hCAP-18/LL-37 was strongly expressed in the stroma of advanced primary and 
secondary PDAC tumours and is secreted by immune cells of the stroma (eg, tumour-associated 
macrophages) in response to TGF-β1 and particularly CSC-secreted Nodal/ActivinA. Treatment of 
pancreatic CSC with recombinant LL-37 increased pluripotency-associated gene expression, self-renewal, 
invasion, and tumourigenicity via formyl peptide receptor 2 (FPR2)- and P2X purinoceptor 7 receptor 
(P2X7R)-dependent mechanisms, which could be reversed by inhibiting these receptors. Importantly, in a 
genetically engineered mouse model of K-Ras-driven pancreatic tumourigenesis, we also showed that 
tumour formation was inhibited by either reconstituting these mice with bone marrow from CRAMP (i.e 
murine homolog of hCAP-18/LL-37) knockout mice or by pharmacologically inhibiting FPR2 and 
P2X7R.  
Conclusion: Thus, hCAP-18/LL-37 represents a previously unrecognized PDAC micro-environment 
factor that plays a critical role in pancreatic CSC-mediated tumourigenesis.  
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SIGNIFICANCE OF THE STUDY 
What is already known on this subject? 
• Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with limited therapeutic options.  
• Pancreatic cancer stem cells (CSCs) are exclusively tumourigenic and highly resistant to 
chemotherapy. 
• Tumour-associated macrophages are important for the progression and metastatic spread of many solid 
tumours. 
What are the new findings? 
• The immuno-modulatory cationic antimicrobial peptide 18/leucine leucine-37 (hCAP-18/LL-37) is 
over expressed in the stroma of PDAC and acts on CSCs to potentiate their inherent biological 
properties. 
• Tumour-associated macrophages secrete hCAP-18/LL-37 in direct response to CSC-secreted 
NODAL/ACTIVINA/TGF-β1. 
• Small molecule targeting of the LL-37 receptors formyl peptide receptor 2 (FPR2) and P2X 
purinoceptor 7 receptor (P2X7R), present on pancreatic CSCs, negatively impacts tumour growth and 
circulating tumour cell numbers. 
How might it impact on clinical practice in the foreseeable future? 
• The discovery of the crucial role of hCAP-18/LL-37 in cancer stem cell biology represents an 
important advancement in our understanding of the PDAC tumour microenvironment.  
• Targeting pancreatic CSCs using inhibitors of the LL-37 receptors FPR2 and P2X7R may represent a 
specific therapeutic approach to block the tumour promoting cross-talk that exists within the tumour 
microenvironment.  
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INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers largely due to its 
high resistance to current treatment strategies[1]. This can at least, in part, be attributed to a subpopulation 
of cells known as pancreatic cancer stem cells (CSCs)[2, 3, 4], which are defined by their cell-intrinsic 
and unlimited self-renewal, exclusive long-term tumourigenicity, capacity to recapitulate the entire cancer 
cell heterogeneity, and metastatic potential[5, 6, 7]. In addition, PDAC is characterized by extensive 
desmoplasia[8], which is made up of heterogeneous cell populations, including pancreatic stellate cells 
(PSCs)[9, 10] and immune cells[8, 11, 12, 13, 14, 15]. This dynamic cellular microenvironment may 
directly or indirectly promote CSCs features[6, 10, 16, 17], but few comprehensive studies have been 
performed in PDAC to date. Thus, we set out to identify stroma-specific paracrine drivers that potentiate 
pancreatic CSC features.  
Here we show that the human cationic anti-microbial protein 18 (hCAP-18, CAMP), the only 
known human cathelicidin alarmin[18, 19, 20], is strongly and exclusively expressed by macrophages 
present within the PDAC stroma. Cleavage of hCAP-18 at the COOH-terminal end gives rise to the 
biologically active 37 amino acid hCAP-18 peptide called leucine leucine-37 (LL-37)[19, 20]. 
Intriguingly, secreted LL-37, via the G protein–coupled receptor, formyl peptide receptor 2 (FPR2)[21, 
22, 23] and P2X(7) purinergic receptor[22], significantly potentiated pancreatic CSC features, such as 
self-renewal, invasion and tumourigenesis. While the factors that mediate LL-37 expression can vary 
based on the biological context, we also show for the first time that CSC-secreted TGF-β family members 
Nodal and ActivinA induce hCAP-18/LL-37 expression in macrophages. Pharmacological or genetic 
inhibition of paracrine activation of pancreatic CSCs by LL-37 markedly reduced their tumourigenicity 
and metastasis in vivo. Thus, our findings not only identify a previously unrecognized tumour 
microenvironment factor that potentiates pancreatic CSC features, but also highlight the potential 
therapeutic impact that targeting this peptide may have on PDAC progression and spread. 
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METHODS 
 Primary human pancreatic cancer cells and macrophages. The use of human material was 
approved by the local ethics committee of each respective hospital or university, and written informed 
consent was obtained from all patients. Tumours were expanded in mice as xenografts (PDX), processed 
and subsequently cultured in vitro as previously detailed[7]. Human blood was obtained from healthy 
donors with informed consent. Monocyte-derived human macrophage cultures were established and 
polarized to an M1 phenotype with GM-CSF as previously described[24, 25, 26].  
Tissue microarrays (TMAs) Four human TMAs containing quadruplicate 1mm cores from a total 
of 42 tumours were constructed. The use of human tissue samples for the construction of the TMAs was 
approved by the Ethics Committee of the Hospital de Madrid Norte Sanchinarro. All 
immunohistochemically-stained sections were assessed and scored by in-house pathologists.  
In vivo assays. The K-Ras
+/LSL-G12D
;Trp53
LSL-R172H
;PDX1-Cre mouse model (KPC) of advanced 
pancreatic cancer has been described previously[27]. B6.129X1-Camp
tm1Rlg
/J mice (CRAMP
–/–
) were 
purchased from Jackson Laboratories (Bar Harbor, Maine) and have been previously described[28]. Mice 
were housed according to institutional guidelines and all experiments were approved by the Animal 
Experimental Ethics Committee of the Instituto de Salud Carlos III (Madrid, Spain).  
Statistical analyses. Results for continuous variables are presented as means ± standard error of 
the mean (SEM) unless stated otherwise. Treatment groups were compared with the independent samples 
t test. Pair-wise multiple comparisons were performed with the one-way ANOVA (two-sided) with 
Bonferroni adjustment. P values <0.05 were considered statistically significant. All analyses were 
performed using SPSS 22.0 (SPSS Inc., Chicago, IL). 
More Materials and Methods can be found as online supplementary information. 
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RESULTS  
Macrophages promote PDAC tumourigenesis and produce hCAP-18/LL-37. To appreciate the 
contributory role of tumour stroma cells in PDAC development, we injected into nude mice 5×105 
primary sphere-derived CSC-enriched PDAC cells alone or with equal numbers of immortalized PSCs, 
primary PSCs or primary human monocyte-derived unpolarized macrophages. No marked differences in 
early tumour growth were observed between primary PDAC cells injected alone or with PSCs. In 
contrast, tumour take and growth was significantly accelerated when PDAC cells were co-injected with 
macrophages (Fig. 1A). Interestingly, at 1.5 weeks human macrophages were no longer detected in these 
tumours as determined by a lack of CD68, CD16 and CD163 staining (data not shown), suggesting that 
the transient presence of human macrophages was sufficient to jumpstart tumour take and promote PDAC 
cell growth in vivo. 
To begin to understand how macrophages might promote PDAC tumour growth, we co-cultured 
human monocyte-derived unpolarized macrophages with and without primary PDAC cells in trans-wells 
(to separate the two cell types) and performed microarray analyses (Table S1). Of the top 25-up-regulated 
genes in macrophages (FDR<10
-4
, logFC>2), 19 genes belonged to the family of interferon-stimulated 
genes (Fig. 1B), while the 6 remaining genes (RSAD2, CMPK2, KRT19, CAMP, SIGLEC1, and ORM1) 
encoded for proteins with diverse functions. We identified hCAP-18/LL-37 (ie, CAMP) as a gene of 
interest as it both encodes for a secreted factor and has been shown to be expressed in other solid tumours, 
including breast[29, 30], lung[31, 32, 33] and ovarian cancers[18, 23, 34], albeit in the epithelial 
compartment. RT-qPCR analysis (Fig. 1C) and immunofluorescence confocal microscopy (Fig. 1D) 
showed up-regulation of hCAP-18/LL-37 in monocyte-derived unpolarized macrophages only when co-
cultured with primary PDAC cells, validating our microarray results. Moreover, while PDAC cells co-
cultured with macrophages did not express hCAP18/LL-37 (data not shown), we observed up-regulation 
of pluripotency-associated genes, which was blocked by the addition of LL-37 blocking antibodies or 
inhibitors, suggesting an LL-37-mediated cross talk between macrophages and CSCs (Fig. 1E and S1).  
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Primary PDAC tumours express hCAP-18/LL-37. Next, we assessed the expression of hCAP-
18/LL-37 by RT-qPCR and immunohistochemical (IHC) analysis in primary PDAC samples. Compared 
to normal pancreas, over expression of hCAP-18/LL-37 mRNA and protein was observed in all PDAC 
samples (Fig. 2A and S2A). Interestingly, only the stroma stained positive for hCAP18/LL-37 while 
cancer cells were negative (Fig. 2A and S2A-C), which is in contrast to what has been reported for other 
carcinomas[18, 29, 31, 35].  
Data were extended using tissue microarrays. The majority (~74%) of ‘normal’ adjacent non-
tumour tissue was negative for hCAP-18/LL-37; however, 81% of PDAC samples stained positive for 
LL-37 with varying degrees of intensity observed between tissues (Fig. 2B-C and S2-S3). Staining of 
serial sections for LL-37, CD16, CD163, CD68 and αSMA demonstrated that tumour infiltrating immune 
cells (ie, macrophages) were the predominant cell type producing hCAP-18/LL-37 (Fig. 2D and S2D-E); 
however, other stromal cells (eg, CD16
+
 neutrophils) also expressed LL-37.  
To allow for a more systematic analysis of pancreatic cancer progression from low to high grade 
PanINs, PDAC lesions, and subsequent metastatic spread we next studied the  
K-Ras
+/LSL-G12D
;Trp53
+/LSLR172H
;PDX-1-Cre (hereafter referred to as KPC)[27] mouse model of PDAC. 
CRAMP (ie, murine homolog of hCAP-18/LL-37) expression in KPC mice was similarly restricted to the 
tumour stroma, absent in normal tissue, and most prominently expressed in primary PDAC lesions and in 
all metastatic lesions of secondary organs, such as the liver (Fig. 2E and S4A). Staining for the 
macrophage markers YM1 or F4/80 also revealed a strong correlation between macrophages and CRAMP 
staining (Fig. 2E, S4B-C).  
CRAMP promotes tumourigenicity of murine PDAC cells in vivo. To test whether CRAMP 
expression is necessary for tumour formation in vivo, we eliminated CRAMP from the hematopoietic 
system of irradiated 5-6 week old KPC mice by syngeneic transplantation of either wild-type or CRAMP 
knockout (CRAMP
–/–
) bone marrow.  While all mice, regardless of the donor bone marrow received, 
showed macrophage infiltration in the pancreas (Fig. S5A), mice transplanted with bone marrow from 
CRAMP
–/–
 mice did not show any CRAMP expression, which does not only suggest excellent 
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transplantation efficiency but also demonstrates that immune cells and not other stromal cells are the 
primary source of CRAMP in PDAC tumours (Fig. 3A). At the tumour level, PDAC tumour tissue and 
severely altered tissue [ie, acinar-to-ductal metaplasia (ADM) and inflammation (Fig. S5B)] were 
significantly reduced in mice transplanted with CRAMP
–/–
 bone marrow compared to controls at 17 
weeks post transplantation (Fig. 3B and S5C).  
To rigorously test the effects of CRAMP on the in vivo CSC compartment, which are exclusively 
capable of tumour initiation and progression[36], we next performed limiting dilution cell transplantation 
assays. Primary syngeneic murine PDAC sphere-derived cells expressing a luciferase reporter were 
transplanted into recipient wild-type and CRAMP
–/–
 mice and tumour formation was determined 5 weeks 
post injection (Fig. 3C, left). While tumours efficiently formed in wild-type mice at dilutions of 10
4
 (4/8) 
and 10
5
 (8/8) cells, only one tumour was detected in CRAMP
–/–
 mice injected with 10
5
 (1/8) cells, 
indicating that the capacity for CSC-initiated tumourigenesis was significantly reduced in CRAMP
–/–
 
mice (Fig. 3C, right). In addition, we found a clear reduction in the percentage of CD133+ cells in the 
tumour formed in the CRAMP
–/–
 mouse (Fig. 3D). To further dissect these phenotypes at the macrophage 
level, we injected 5×105 primary sphere-derived CSC-enriched murine PDAC cells alone or with equal 
numbers of monocyte-derived unpolarized macrophages isolated from wild-type or CRAMP
–/–
 mice. 
After 4 weeks, tumour take and growth was significantly accelerated when murine PDAC cells were co-
injected with wild-type macrophages [similar to what was observed when human macrophages were co-
injected with human PDAC cells (Fig. 1A)], but not with CRAMP
–/–
 macrophages (Fig. 3E). In line with 
these observations, murine PDAC sphere formation was consistently enhanced in the presence of wild-
type macrophages versus CRAMP
–/–
 macrophages (Fig. S5D), suggesting that CRAMP 
enhances/promotes PDAC tumour take and progression by potentiating CSC in vivo self-renewal and 
tumourigenesis. 
hCAP18/LL-37 has inherent pro-CSC properties. Stimulated by these proof-of-concept studies, 
we next aimed to further dissect the mechanisms of action for LL-37 on human pancreatic cancer (stem) 
cells. Using the established CSC cell surface marker CD133[2] and a novel biomarker for CSC, 
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autofluorescence[5], we found that treatment of primary xenograft-derived PDAC cultures with 
recombinant LL-37 peptide (rLL-37) resulted in a consistent ~2-fold enrichment in the CD133+ (Fig. 4A 
and S6A) and autofluorescent populations (Fig. 4B and S6A), suggesting that LL-37 increases the CSC 
pool. Indeed, colony-forming (Fig. 4C), and sphere-forming efficiency (Fig. 4D) were both significantly 
enhanced by rLL-37; the latter even more pronounced during serial passaging, which further enriches for 
CSCs (Fig. 4D). Treatment also resulted in over expression of KLF4, SOX2, OCT3/4, and NANOG in 
rLL-37-treated spheres (Fig. 4E and S6B-C). Of note, recombinant CRAMP functioned similarly to rLL-
37 in CSCs derived from KPC mouse pancreatic tumours (Fig. S7). Lastly and in line with a pro-CSC 
effect, rLL-37 also increased the inherent chemoresistant potential of CSCs, as measured by increased 
CD133+ cells following treatment with Gemcitabine or Abraxane (Fig. 4F and S8).  
Importantly, the most defining feature of CSCs lies in their ability to form tumours in vivo. 
Sphere-derived PDAC cells pre-treated with rLL-37 revealed consistently enhanced tumourigenicity, a 
higher CSC frequency, and increased early tumour take as compared to scrambled peptide-treated cells. 
Notably, this effect was particularly evident when low cell numbers (~10 cells) were injected (Fig. 5A-B). 
In line with our hypothesis that the effects of LL-37 are preferentially affecting CSCs, when we injected 
adherent cells, which contain few CSCs[6], the differences in tumourigenicity between non-treated and 
rLL-37-treated cells were not as striking (sphere-derived cells: 10.2-fold [CI 10.1-10.4] increase in CSC 
frequency; adherent cells: 1.4-fold [CI 1.3-1.5] increase in CSC frequency) (Fig. S9). Lastly and to more 
rigorously test the hypothesis that LL-37 more specifically promotes CSCs, we assessed the sphere 
forming capacity and cell cycle profile of CD133+ CSC and their CD133– counterparts in the absence or 
presence of rLL-37. Indeed, our data confirm that LL-37 preferentially targets and potentiates CSC self-
renewal and proliferation (Fig. 5C-D).  
LL-37 promotes CSC invasiveness. We found the highest expression of LL-37 and CRAMP in 
primary PDAC tumours and metastatic lesions of human and mouse origins (Fig. 2), respectively, 
suggesting that LL-37 is likely important late during PDAC progression and may be involved in EMT. 
Supporting this hypothesis, rLL-37 treatment increased the CXCR4+ subpopulation (Fig. 6A) present in 
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CSCs, a subpopulation of CSCs that drives metastasis[2]. Analysis of EMT-related genes following rLL-
37 treatment revealed down-regulation of E-cadherin and up-regulation of Vimentin and Snail (Fig. 6B-
C), and rLL-37 treatment also increased migration (Fig. 6D) and invasion of CSCs (Fig. 6E). Of 
particular interest, chemoattraction of invading rLL-37-treated sphere-derived PDAC cells by the CXCR4 
ligand SDF-1 was evident even at very low concentrations (eg, 1ng/mL), which had no impact on control 
cells. To validate this in vivo, we intraspleenically injected rLL-37 pre-treated CSCs stably expressing a 
luciferase reporter and observed increased dissemination (ie, micro-metastases) of cells pre-treated with 
rLL-37 to the liver  (Fig. 6F-G and S10). 
Macrophages express hCAP-18/LL-37 in response to CSC-secreted TGF-β1 family members. 
Macrophages (ie, TAMs), as one of the primary sources of LL-37 in vivo, may respond to cues from the 
tumour (eg, CSC) to drive the expression of LL-37. To further dissect this putative CSC-TAM crosstalk, 
we modeled the tumour in vivo microenvironment by first polarizing monocyte-derived human 
macrophages towards an ‘M1’ phenotype with GM-CSF[24] prior to exposing them to CSC-conditioned 
media (CM). Intriguingly, ‘M1’ macrophages exposed to CSC CM up-regulated LL-37 (Fig. 7A-B) and 
underwent a morphological change from a classic circular morphology to a more elongated shape (Fig. 
7C). This change was accompanied by induction of alternatively-activated/‘M2’ genes, such as oncostatin 
M (OSM) and VEGF (Fig. 7D) as well as fluctuations in the expression of the cell surface M2 
macrophage markers CD163, CD204 and CD206[37, 38, 39] (Fig. S11).  
TGF-β can polarize ‘M1’ macrophages to an ‘M2’/alternatively activated phenotype[40] and 
cancer cells, including PDAC cells do secrete large amounts of TGF-β (Fig. S12A)[41]. As many 
advanced PDAC tumours harbor inactivating mutations in the TGF-β signaling pathway rendering them 
unresponsive[42], we reasoned that TGF-β secreted by PDAC cells may instead primarily act on 
macrophages inducing LL-37 expression. In addition, we recently showed that PDAC CSC over express 
other member of the TGF-β superfamily, namely Nodal/ActivinA[6], which may also be implicated in the 
macrophage-CSC-crosstalk. Indeed, pre-treatment of M1-polarized GM-CSF-treated monocyte-derived 
human macrophages with the TGFβ family members Nodal/ActivinA or TGF-β significantly increased 
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LL-37 levels (Fig. 7E-F) as well as alternatively-activated/‘M2’ genes, such as OSM and VEGF (Fig. 
7G) and phospho-p38, NFB phospho-p50 and the transcription factor vitamin D receptor (VDR) (Fig. 
S12B-C), the latter three of which have been shown to regulate hCAP18/LL-37 expression. Blocking 
Nodal/ActivinA/TGF-β signaling in CSC CM-treated macrophages with SB431542 and SB505124, 
both of which are inhibitors of the respective receptors Activin-like 4 (Alk4) and Alk5, abolished the 
enhanced expression of LL-37 and additional target genes (Fig. 7H).  
Targeting LL-37 signaling impairs CSC tumourigenesis. hCAP-18/LL-37 is believed to exert its 
effects through the receptors FPR2[21, 22] and/or P2X7R[22, 43] (Fig. 8A), both of which were 
detectable at the mRNA level and by flow cytometry in several primary PDAC cultures (Fig. 8B-C and 
Fig. S13A). Receptor expression was restricted to a small subpopulation of adherent cells (less than 1%), 
which increased when cells were cultured as spheres (2-5%) and treated with rLL-37 (4-8%). More 
importantly, the expression of both receptors was primarily (>60%) restricted to CD133+ cells (Fig. 8C 
and Fig. S13A). The latter was particularly evident in a freshly digested PDAC patient tumour (Fig. 
S13B). These data together suggest an enrichment of these receptors in CSCs. Using inhibitors specific 
for both FPR2 and P2X7R (WR-W4 and KN-62, respectively), LL-37-induced colony formation (Fig. 
8D), invasion (Fig. 8E) and CD133+ cell expansion (Fig. 8F) was reduced with each inhibitor alone or in 
combination, confirming that the effects of LL-37 are indeed mediated through these receptors.  
To rigorously test the therapeutic potential of anti-LL-37 therapy in vivo, we treated KPC or 
KPCR (KPC mice that additionally express a pancreas-specific RFP reporter) mice with WR-W4 and 
KN-62 for either 5 weeks (short-term) or 16 weeks (long-term) (Fig. 9A). With as little as 5 weeks of 
treatment, there was a marked reduction in the number of RFP+ circulating tumour cell of KPCR mice 
(Fig. 9B). In addition, we observed reduced numbers of low-grade PanINs and significantly fewer high-
grade PanINs and PDAC lesions (Fig. 9C) in treated mice. Of note, no liver metastases were detected in 
either group at this stage. By extending our treatment to 16 weeks, the number of CTCs (EPCAM+) in 
treated mice were still reduced (Fig. 9D). With respect to the pancreas, while no impact on the incidence 
of low-grade PanINs was observed, we still quantified significantly fewer high-grade PanINs and PDAC 
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lesions (Fig.9E) in treated mice. In addition, and in line with our CTC analyses, liver metastases were 
histologically detected in 75% of untreated mice, while only one treated mouse developed liver metastasis 
(data not shown). These results, in their entirety, highlight the promising therapeutic potential of 
targeting LL-37 signaling in PDAC. 
 
CONCLUSION / DISCUSSION 
While the PDAC tumour microenvironment is composed of many different cells, TAMs are likely 
one of the most dynamic resident cells of the tumour stroma[12, 13, 14, 16, 17, 39, 44, 45]. Not only can 
they enhance tumour growth when co-injected in vivo, but our microarray analyses additionally showed 
that monocyte-derived human macrophages are transcriptionally re-programmed by PDAC cells. For 
example, macrophages up-regulated a large number of genes belonging to the family of interferon-
stimulated genes (OAS, MX1, ISG15, etc.), which we hypothesize is due to IFN-β produced by PDAC 
cells[46], similar to what has been shown for other Kras-transformed tumours[47]. Macrophages also 
down-regulated the expression of chemokines and pro-inflammatory genes, such as CXCL1, CXCL2, IL-
1 and IL-6, as well as macrophage M1 markers, such as CD68, thus providing a first indication that 
PDAC cells alter the differentiation/polarization state of macrophages. Most intriguingly, however, 
macrophages also up-regulated the expression of hCAP18/LL-37, a peptide previously reported to be 
either pro- or anti-tumourigenic in other cancer models[18, 29, 48, 49], but had not yet been studied in the 
context of pancreatic CSC to date and revealed several interesting and novel findings. 
The antimicrobial peptide hCAP18/LL-37 was detectable across a large set of PDAC tumours at 
both the mRNA and protein level, and its expression was most prominent in PDAC and secondary 
metastatic lesions. hCAP18/LL-37 was originally identified as a host immune anti-microbial defensin 
molecule and is constitutively secreted by a variety of immune cells (eg, neutrophils and macrophages), 
but can also be expressed by epithelial cells and fibroblasts[50]. Interestingly, human and murine PDAC 
epithelial cells were univocally negative for hCAP18/LL-37 or CRAMP, respectively, although previous 
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studies examining breast, lung, and ovarian cancers had shown that hCAP18/LL-37 is expressed by the 
tumour epithelium[18, 29]. Instead, in PDAC, expression of hCAP18/LL-37 was clearly restricted to the 
tumour stroma, revealing a previously unappreciated and important difference between tumour entities 
with respect to the source of hCAP18/LL-37 expression. We predict that PDAC cells may be deficient in 
certain signaling factors that are necessary for hCAP18/LL-37 expression, such as vitamin D activated 
PPARγ signaling[51], NF-κB-mediated CCAAT/enhancer-binding protein α (C/EBP) activation via 
MAPK-mediated phosphorylation[52], or other yet unidentified pathways. Within the tumour stroma, we 
identified macrophages as the primary source of LL-37; however, polymorphonuclear neutrophils can 
also secrete LL-37[50] and have been shown to be one of the many types of tumour infiltrating cells 
detected in pancreatic neoplasias[53]. Thus, while we focused on TAMs, we note that other immune 
infiltrating cells likely also produce LL-37 in vivo.  
LL-37 has been shown to signal through P2X7R and FPR2[21, 22, 23], both of which were 
detectable on the surface of PDAC cells, and their expression were primarily restricted to CSCs (ie, 
CD133+ cells). As CSCs are the driving subpopulation of cells in PDAC with exclusive tumourigenic 
potential, and since tumour take and growth was significantly increased when PDAC cells were co-
injected with macrophages, we thus reasoned that macrophages potentiate tumour growth via an LL-37-
mediated pro-CSC mechanism. We confirmed this hypothesis in vivo by using CRAMP knockout mice as 
a source of bone marrow for transplantation experiments in irradiated KPC mice, as a syngeneic model to 
study CSC-mediated tumour take and growth or as a source of monocyte-derived macrophages for co-
injection tumourigenicity studies with murine PDAC CSCs.  All three approaches conclusively 
demonstrated that CRAMP is necessary for CSC-mediated PDAC development and progression in vivo. 
Importantly, these results are in agreement with those published by Li et al., where they show that 
cathelicidin (ie, CRAMP) expressed from murine myeloid cells promotes cigarette smoke-induced lung 
tumour growth in vivo[32, 33].  
To validate the biological relevance of our in vivo findings in the human setting, we showed that 
rLL-37 increased the CSC pool using two independent markers for CSCs (ie, CD133 and 
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autofluorescence). This apparent activation/stimulation of the CSC compartment was validated at the 
functional level and during in vivo limiting dilution tumourigenicity assays, where we demonstrate that 
rLL-37 treatment increases sphere-derived CSC-mediated tumour formation and fitness. While sphere-
derived cells are enriched in CSCs, tumour growth following injection of low numbers of sphere-derived 
cells is rarely achieved at single digit numbers. Treatment of cells with rLL-37, however, further 
expanded the CSCs pool during sphere culture translating into a significantly higher CSC frequency and 
an apparent increase in viability, such that when injected at low numbers CSCs were able to survive in the 
recipient host and form tumours. In addition, while it is known that the population of CD133+ CSCs 
enrich during chemotherapy, we show that rLL-37 treatment further augments this enrichment in the 
presence of either Gemcitabine or Abraxane, arguing that LL-37 can enhance the inherent 
chemoresistance of CSCs. These results parallel those of Acharyya S et al., wherein they show that the 
chemokine S100A8/9, secreted by myeloid cells in the breast cancer microenvironment, also enhances 
cancer cell chemoresistance[54].  
LL-37 treatment also activated an EMT-like profile in CSCs. We observed increased 
phosphorylation of the kinases ERK1/2, AKT and PKC within 10 minutes of rLL-37 treatment in CSCs, 
and the EMT transcriptional mediators Vimentin and Snail were additionally up-regulated. At the 
functional level, rLL-37 treatment increased cell motility and invasion and more importantly increased 
metastasis in vivo. Of particular interest was the observation that rLL-37-treated CSCs were able to 
invade towards the chemo-attractant SDF-1 at concentrations of only 1ng/mL, while invasion of control 
cells required 100ng/mL, a concentration that is hardly relevant in vivo. Wu et al., reported that rLL-37 
enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient by CXCR4 cell 
surface stabilization[55]. In line with these findings, we observed a 3-fold increase in CXCR4 cell 
membrane expression in rLL-37-treated cells, indicating that LL-37 likely primes CSCs for the SDF-
1/CXCR4 axis via a similar CXCR4-dependent mechanism.  
Members of the TGF-β superfamily, namely Bone Morphogenic Proteins, TGF-β, and 
Nodal/ActivinA, exert multiple and sometimes opposing effects on a variety of cell types. We have 
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previously shown that TGF-β and Nodal/ActivinA are produced by PDAC CSCs and stromal cells[10], 
while only Nodal/ActivinA directly promote CSC-mediated tumourigenesis[6]. In this study we 
demonstrate that these CSC-secreted factors also stimulate macrophages in a paracrine fashion. For 
example, treatment of ‘M1’-polarized macrophages with CSC-conditioned media rapidly polarized 
macrophages towards an alternatively activated phenotype at the morphological, transcriptional and cells 
surface receptor level. More importantly, we also observed a marked increase in hCAP18/LL-37 mRNA and 
protein expression following treatment. While Li et al., also showed that ovarian cancer cells can activate in 
vitro cultured macrophages to produce hCAP18/LL-37 via cancer cell secreted versican V1[33], we did not 
detect expression of versican V1 in our primary PDAC cultures (data not shown). Instead, we identified 
TGF-β, Nodal and ActivinA as the factors responsible for CSC-mediated activation of macrophages, and 
inhibitors of both the TGF-β and Nodal/Activin receptors (Alk5 and Alk4, respectively) could reverse the 
effects in vitro and in vivo (data not shown). While the transcriptional regulation of hCAP18/LL-37 
expression has not been fully elucidated, the CAMP gene is a direct target of the VDR transcription 
factor[33, 56] and hCAP/LL-37 expression has also been shown to be regulated by NFkB phospho-p50 and 
phospho-p38[52].  In macrophages treated with CSC-conditioned media or TGF-β, Nodal and ActivinA, 
NFkB phospho-p50 and phospho-p38 activation was observed as well as transcriptional upregulation of 
VDR, implicating these factors as common mediators by which TGF-β superfamily members regulate LL-
37 expression and thus promote formation of a pro-CSC niche.  
Targeting the tumour microenvironment has gained enormous attention over the past decade, 
particularly the development of agents that can disrupt the crosstalk between cancer cells and the stroma. 
Having determined that the majority of cells expressing LL-37 receptors are also CD133+, we tested the 
efficacy of targeting FPR2 and P2X7R in the clinically relevant KPC PDAC mouse model. We observed 
that in mice treated with WR-W4 and KN-62, high grade PanIN and PDAC lesions were significantly 
reduced, and CTCs were essentially eliminated from the blood of treated mice, confirming that LL-37 
signaling is indeed important for PDAC tumour progression and dissemination. It is important to note that in 
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the intervention studies performed in KPC mice we cannot rule out the fact that the treatments used may 
have also targeted TAMs, which also express FPR2 and P2X7R. Nevertheless, our data provide clear proof 
of principle for targeting these LL-37 receptors, although more studies will be needed to understand how 
WR-W4 and KN-62 reduced PDAC progression in vivo (ie, at the level of the cancer cell, TAM or both).  
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FIGURE LEGENDS 
Figure 1: Macrophages promote PDAC tumour take and growth. (A) Summary of in vivo tumour 
take and growth 3 weeks post subcutaneous injection of sphere-derived CSC-enriched PDAC cells with 
or without human monocyte-derived unpolarized macrophages (MØ), immortalized PSCs (iPSCs) or 
primary PSCs (pPSCs) (n=4 mice/group). (B) Heatmap of top 25 genes up-regulated and down-regulated 
(FDR<10
-4
, logFC > 2) in primary human monocyte-derived macrophages co-cultured with Panc185 
(1), Panc354 (2) or Panc215 (3) in a trans-well assay for 48h. (C) RT-qPCR analysis of hCAP18/LL-37 
mRNA levels in human monocyte-derived macrophages alone or co-cultured with indicated PDAC cells 
for 48h. (D) Immunofluorescence analysis of CD16 (macrophage marker) and LL-37 in human 
monocyte-derived macrophage-PDAC cell co-cultures. White dashed line marks the perimeter of a PDAC 
colony. Scale bar = 100µm. (E) RT-qPCR analysis of Oct3/4 and Nanog mRNA levels in Panc215 and 
Panc185 cultures following 48h co-cultivation with primary human monocyte-derived macrophages in a 
trans-well assay.  
Figure 2: LL-37 expression is restricted to the tumour stroma and correlates with advanced 
neoplastic lesions. (A) RT-qPCR analysis of hCAP18/LL-37 mRNA levels in a panel of surgically 
resected human primary PDAC tumours (n=30 tumours) and cultures. WB analysis of hCAP18/LL-37 
protein expression in a subgroup of samples (inset). (B) hCAP18/LL-37 expression profile in a TMA 
panel containing normal, PanIN (I-III), PDAC, metastases and pancr atitis cores. (C) Representative 
micrographs of hCAP18/LL-37-stained TMA cores. (D) Serial sections of a PDAC TMA core stained for 
hCAP18/LL-37, the macrophage markers CD16, and the PSC marker αSMA. (E) Immunohistological 
analysis of CRAMP (murine ortholog of LL-37) and YM1 (macrophage marker) expression in 26-week 
old KPC mouse pancreas and liver. Scale bars = 200 and 50µm (insets). nPanc = normal pancreas. 
Figure 3: CRAMP affects PDAC tumour growth in vivo. (A) IHC analysis of CRAMP expression in 
representative FFPE sections from pancreata of 22-23-week old KPC mice transplanted with bone 
marrow from wild-type control C57Bl/6 mice or CRAMP
–/–
 mice (n=4 mice/group). (B) Quantification of 
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tissue area in mouse pancreata from 22-23-week old KPC mice transplanted with bone marrow from 
wild-type control C57Bl/6 mice (n=4 mice) or CRAMP
–/–
 mice (n=4 mice/group), categorized as normal 
acinar tissue, severely altered tissue (ADM and inflammation) or tumour tissue (PanINs I-III and PDAC) 
(Fig. S5B). Representative images of tumour tissue (right). (C and D) Wild-type and CRAMP
–/–
 mice 
were subcutaneously injected with the indicated number of primary murine PDAC cells (ie, CHX-BC-
RFP-Luc cells) in Matrigel
TM
 (n=8 injections/group). Tumour take was determined 5 weeks post-injection 
(left) by BLI assessment (C). Representative BLI pictures of mice 5 weeks post injection with indicated 
numbers of murine PDAC cells (left). Summary of in vivo tumour take and growth (right). CSC 
frequencies determined using the extreme limiting dilution analysis algorithm  
(http://bioinf.wehi.edu.au/software/elda/index.htmL) (right, 95% CI). (D) Tumours from mice injected 
with 10
5
 murine PDAC cells were excised and CD133 content within the RFP+ population was 
determined. Quantification of the percent of cells expressing CD133 is graphed (top) and representative 
cytometry plots are shown (bottom). (E) Summary of in vivo tumour take and growth of subcutaneously-
injected 5×105 sphere-derived CSC-enriched murine PDAC cells with or without murine monocyte-
derived unpolarized macrophages (MØ) isolated from wild-type (wt) CRAMP
+/+
 mice or CRAMP
–/–
 mice 
(n=8 mice/group). n.s. = not significant. 
Figure 4: LL-37 expands the CSC pool. (A and B) Primary sphere-derived PDAC cultures were treated 
with rLL-37 and the percentage of (A) CD133+ cells and (B) autofluorescent cells was measured by flow 
cytometry. (C and D) Effects of rLL-37 on CSC (C) colony formation and (D) serial sphere formation. 
(E) RT-qPCR analysis of pluripotency-associated genes in sphere-derived PDAC cells after stimulation 
with rLL-37. (F) Percentage of CD133+ cells in control vs. Gemcitabine (GEM)-treated (0.1µg/mL) or 
Gemcitabine and rLL-37-treated (5µg/mL) primary PDAC cells (top), as determined by flow cytometric 
analysis (bottom). 
Figure 5: LL-37 enhances functional CSC properties. (A and B) Mice were subcutaneously injected 
with the indicated number of scrambled or rLL-37 peptide (10µg/mL) pre-treated CSCs resuspended in 
Matrigel
TM
 (n=4 mice/dilution/group). (A) Tumour take was determined 10 weeks post-injection (left). 
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Images of resected tumours and CSC frequencies determined using the extreme limiting dilution analysis 
algorithm  (http://bioinf.wehi.edu.au/software/elda/index.htmL) (right, 95% CI). (B) Summary of in vivo 
tumour take and growth. (C) Primary PDAC cells were sorted for the CSC marker CD133, treated with 
rLL-37 or a scrambled peptide control, cultured as spheres in anchorage independent conditions and 
sphere numbers determined 7 days later (n.s. = not significant). (D) Proliferation, as detected by BrdU 
staining, in CD133+ and CD133– PDAC cells after stimulation with rLL-37.  
Figure 6: LL-37 promotes EMT and CSC invasiveness. (A) Flow cytometry analysis of CXCR4 cell 
surface expression in 2 primary PDAC cultures treated with rLL-37. (B) RT-qPCR analysis of EMT 
genes in sphere-derived PDAC cells after stimulation with rLL-37. (C) Western blot analysis of E-
cadherin, vimentin and GAPDH in PDAC cells after stimulation with rLL-37 (left) and densitometric 
analysis of blots (right). RDU = relative density units. (D) Scratch wound assay of PDAC cells after 
stimulation with rLL-37. Representative micrographs (left) and quantification of wound size 12h after 
wound induction (right). (E) Representative images of invaded cells (left) and quantification of invaded 
rLL-37-treated PDAC cells through Matrigel
TM
 following stimulation with 20% FBS (+Ctl), media alone 
(-Ctl) or increasing concentration of SDF-1 (right). (F) PDAC cells dissemination in vivo, assessed by 
noninvasive bioluminescence imaging (BLI) at 10 weeks after intrasplenic injection of luciferase 
expressing rLL-37-treated (10µg/mL) PDAC cells in NOD scid IL2 receptor γ chain knockout (NSG) 
mice (tops) and BLI assessment of PDAC cell dissemination to the liver (bottoms) (n=5 mice/group). 
(G) Dissemination of PDAC-luciferase cells to the liver was further verified by measuring luciferase 
activity in explanted and homogenized tissues, expressed as relative light units (RLUs)/mg of total 
protein. 
Figure 7: Macrophages express hCAP-18/LL-37 in response to CSC-secreted TGF-β1, Nodal and 
ActivinA. (A) RT-qPCR analysis of hCAP18/LL-37 mRNA levels in human monocyte-derived 
macrophages cultured with control media or CSC conditioned-media (CM). (B) Western blot analysis of 
hCAP18/LL-37 and GAPDH in human monocyte-derived macrophages cultured with control media or 
CSC CM (left) and corresponding densitometric analysis (right). (C) Representative micrographs of 
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primary monocyte-derived macrophages cultured with control media or CSC CM. (D) RT-qPCR analysis 
of hCAP18/LL-37, OSM and VEGF mRNA expression levels in human monocyte-derived macrophages 
cultured with control media or with CSC CM from 3 primary PDAC cultures. (E-G) Primary human 
monocyte-derived macrophages were cultured with control media or with CSC CM, TGF-β (1ng/mL), 
Nodal (300 g/mL) and ActivinA (100ng/mL) or a combination of all three. (E) RT-qPCR analysis of 
hCAP18/LL-37 mRNA levels, (F) western blot analysis of hCAP18/LL-37, pSmad2, total Smad2 and 
GAPDH, (G) RT-qPCR analysis of OSM and VEGF mRNA levels. (H) RT-qPCR analysis of 
hCAP18/LL-37, OSM and VEGF mRNA levels in primary human monocyte-derived macrophages pre-
treated for 1 h with a diluent control (Ctl), SB431542 (20µM) or SB505124 (20µM) and subsequently 
cultured for 48h with control media, CSC CM, TGF-β (1ng/mL), or Nodal (300ng/mL) and Activin 
(100ng/mL). n.s. = not significant. 
Figure 8: Targeting LL-37 receptors inhibit CSC phenotypes. (A) Diagram of the cross-talk between 
macrophages and CSCs, receptors and secreted factors involved, and specific inhibitors of these 
pathways. (B) RT-qPCR analysis of FPR2 and P2X7R mRNA levels in 3 primary PDAC cultures. (C) 
Flow cytometry analysis of P2X7R cell surface expression in 2 primary PDAC lines cultured as adherent 
or sphere cultures and treated with rLL-37. Percentage of CD133-positive cells within the P2X7R-
positive subpopulation is shown in the right panels. (D and E) LL-37-treated sphere-derived PDAC cells 
were pre-treated with diluent control or WR-W4, KN-62 or a combination of both and (D) colony 
formation on Matrigel
TM
, (E) invasion through Matrigel
TM
 following stimulation with SDF-1 (+Ctrl = 
20% FBS; –Ctrl = media alone) or (F) the percentage of CD133-positive cells measured by flow 
cytometry was determined. 
Figure 9: Targeting LL-37 receptors inhibit PDAC development in vivo. (A) Experimental setup for 
in vivo short-term and long-term treatment. (B) Analysis of serum CTCs (RFP+). Representative flow 
cytometry plots are shown (left) and quantification of the frequency of circulating tumour cells/lineage 
negative cells following 5 weeks of treatment are shown (right) (n=4 mice/group).  (C) Representative 
images of mouse pancreata from control (n=4 mice) vs. treated (n=4 mice) KPC mice after 5 weeks of 
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treatment (left). Quantitative analysis of PanIN/PDAC frequency and grading (right). n.s. = not 
significant. (D) Analysis of serum CTCs (EPCAM+). Representative flow cytometry plots are shown 
(left) and quantification of the frequency of circulating tumour cells/lineage negative cells following 16 
weeks of treatment are shown (right) (n=4 mice/group).  (E) Representative images of mouse pancreata 
from control (n=4 mice) vs. treated (n=4 mice) KPC mice after 16 weeks of treatment (left). Quantitative 
analysis of PanIN/PDAC frequency and grading (right).  
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Figure 1: Macrophages promote PDAC tumour take and growth. (A) Summary of in vivo tumour take and 
growth 3 weeks post subcutaneous injection of sphere-derived CSC-enriched PDAC cells with or without 
human monocyte-derived unpolarized macrophages (MØ), immortalized PSCs (iPSCs) or primary PSCs 
(pPSCs) (n=4 mice/group). (B) Heatmap of top 25 genes up-regulated and down-regulated (FDR<10-4, 
|logFC| > 2) in primary human monocyte-derived macrophages co-cultured with Panc185 (1), Panc354 (2) 
or Panc215 (3) in a trans-well assay for 48h. (C) RT-qPCR analysis of hCAP18/LL-37 mRNA levels in human 
monocyte-derived macrophages alone or co-cultured with indicated PDAC cells for 48h. (D) 
Immunofluorescence analysis of CD16 (macrophage marker) and LL-37 in human monocyte-derived 
macrophage-PDAC cell co-cultures. White dashed line marks the perimeter of a PDAC colony. Scale bar = 
100µm. (E) RT-qPCR analysis of Oct3/4 and Nanog mRNA levels in Panc215 and Panc185 cultures following 
48h co-cultivation with primary human monocyte-derived macrophages in a trans-well assay.  
388x513mm (72 x 72 DPI)  
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Figure 2: LL-37 expression is restricted to the tumour stroma and correlates with advanced neoplastic 
lesions. (A) RT-qPCR analysis of hCAP18/LL-37 mRNA levels in a panel of surgically resected human primary 
PDAC tumours (n=30 tumours) and cultures. WB analysis of hCAP18/LL-37 protein expression in a subgroup 
of samples (inset). (B) hCAP18/LL-37 expression profile in a TMA panel containing normal, PanIN (I-III), 
PDAC, metastases and pancreatitis cores. (C) Representative micrographs of hCAP18/LL-37-stained TMA 
cores. (D) Serial sections of a PDAC TMA core stained for hCAP18/LL-37, the macrophage markers CD16, 
and the PSC marker αSMA. (E) Immunohistological analysis of CRAMP (murine ortholog of LL-37) and YM1 
(macrophage marker) expression in 26-week old KPC mouse pancreas and liver. Scale bars = 200 and 50µm 
(insets). nPanc = normal pancreas.  
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Figure 3: CRAMP affects PDAC tumour growth in vivo. (A) IHC analysis of CRAMP expression in 
representative FFPE sections from pancreata of 22-23-week old KPC mice transplanted with bone marrow 
from wild-type control C57Bl/6 mice or CRAMP–/– mice (n=4 mice/group). (B) Quantification of tissue area 
in mouse pancreata from 22-23-week old KPC mice transplanted with bone marrow from wild-type control 
C57Bl/6 mice (n=4 mice) or CRAMP–/– mice (n=4 mice/group), categorized as normal acinar tissue, 
severely altered tissue (ADM and inflammation) or tumour tissue (PanINs I-III and PDAC) (Fig. S5B). 
Representative images of tumour tissue (right). (C and D) Wild-type and CRAMP–/– mice were 
subcutaneously injected with the indicated number of primary murine PDAC cells (ie, CHX-BC-RFP-Luc cells) 
in Matrigel™ (n=8 injections/group). Tumour take was determined 5 weeks post-injection (left) by BLI 
assessment (C). Representative BLI pictures of mice 5 weeks post injection with indicated numbers of 
murine PDAC cells (left). Summary of in vivo tumour take and growth (right). CSC frequencies determined 
using the extreme limiting dilution analysis algorithm  (http://bioinf.wehi.edu.au/software/elda/index.html) 
(right, 95% CI). (D) Tumours from mice injected with 105 murine PDAC cells were excised and CD133 
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content within the RFP+ population was determined. Quantification of the percent of cells expressing CD133 
is graphed (top) and representative cytometry plots are shown (bottom). (E) Summary of in vivo tumour 
take and growth of subcutaneously-injected 5×105 sphere-derived CSC-enriched murine PDAC cells with or 
without murine monocyte-derived unpolarized macrophages (MØ) isolated from wild-type (wt) CRAMP+/+ 
mice or CRAMP–/– mice (n=8 mice/group). n.s. = not significant.  
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Figure 4: LL-37 expands the CSC pool. (A and B) Primary sphere-derived PDAC cultures were treated with 
rLL-37 and the percentage of (A) CD133+ cells and (B) autofluorescent cells was measured by flow 
cytometry. (C and D) Effects of rLL-37 on CSC (C) colony formation and (D) serial sphere formation. (E) RT-
qPCR analysis of pluripotency-associated genes in sphere-derived PDAC cells after stimulation with rLL-37. 
(F) Percentage of CD133+ cells in control vs. Gemcitabine (GEM)-treated (0.1µg/mL) or Gemcitabine and 
rLL-37-treated (5µg/mL) primary PDAC cells (top), as determined by flow cytometric analysis (bottom).  
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Figure 5: LL-37 enhances functional CSC properties. (A and B) Mice were subcutaneously injected with the 
indicated number of scrambled or rLL-37 peptide (10µg/ml) pre-treated CSCs resuspended in Matrigel™ 
(n=4 mice/dilution/group). (A) Tumour take was determined 10 weeks post-injection (left). Images of 
resected tumours and CSC frequencies determined using the extreme limiting dilution analysis 
algorithm  (http://bioinf.wehi.edu.au/software/elda/index.html) (right, 95% CI). (B) Summary of in vivo 
tumour take and growth. (C) Primary PDAC cells were sorted for the CSC marker CD133, treated with rLL-37 
or a scrambled peptide control, cultured as spheres in anchorage independent conditions and sphere 
numbers determined 7 days later (n.s. = not significant). (D) Proliferation, as detected by BrdU staining, in 
CD133+ and CD133– PDAC cells after stimulation with rLL-37.  
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Figure 6: LL-37 promotes EMT and CSC invasiveness. (A) Flow cytometry analysis of CXCR4 cell surface 
expression in 2 primary PDAC cultures treated with rLL-37. (B) RT-qPCR analysis of EMT genes in sphere-
derived PDAC cells after stimulation with rLL-37. (C) Western blot analysis of E-cadherin, vimentin and 
GAPDH in PDAC cells after stimulation with rLL-37 (left) and densitometric analysis of blots (right). RDU = 
relative density units. (D) Scratch wound assay of PDAC cells after stimulation with rLL-37. Representative 
micrographs (left) and quantification of wound size 12h after wound induction (right). (E) Representative 
images of invaded cells (left) and quantification of invaded rLL-37-treated PDAC cells through MatrigelTM 
following stimulation with 20% FBS (+Ctl), media alone (-Ctl) or increasing concentration of SDF-1 (right). 
(F) PDAC cells dissemination in vivo, assessed by noninvasive bioluminescence imaging (BLI) at 10 weeks 
after intrasplenic injection of luciferase expressing rLL-37-treated (10µg/ml) PDAC cells in NOD scid IL2 
receptor γ chain knockout (NSG) mice (tops) and BLI assessment of PDAC cell dissemination to the liver 
(bottoms) (n=5 mice/group). (G) Dissemination of PDAC-luciferase cells to the liver was further verified by 
measuring luciferase activity in explanted and homogenized tissues, expressed as relative light units 
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(RLUs)/mg of total protein.  
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Figure 7: Macrophages express hCAP-18/LL-37 in response to CSC-secreted TGF-β1, Nodal and ActivinA. (A) 
RT-qPCR analysis of hCAP18/LL-37 mRNA levels in human monocyte-derived macrophages cultured with 
control media or CSC conditioned-media (CM). (B) Western blot analysis of hCAP18/LL-37 and GAPDH in 
human monocyte-derived macrophages cultured with control media or CSC CM (left) and corresponding 
densitometric analysis (right). (C) Representative micrographs of primary monocyte-derived macrophages 
cultured with control media or CSC CM. (D) RT-qPCR analysis of hCAP18/LL-37, OSM and VEGF mRNA 
expression levels in human monocyte-derived macrophages cultured with control media or with CSC CM 
from 3 primary PDAC cultures. (E-G) Primary human monocyte-derived macrophages were cultured with 
control media or with CSC CM, TGF-β1 (1ng/mL), Nodal (300ng/mL) and ActivinA (100ng/mL) or a 
combination of all three. (E) RT-qPCR analysis of hCAP18/LL-37 mRNA levels, (F) western blot analysis of 
hCAP18/LL-37, pSmad2, total Smad2 and GAPDH, (G) RT-qPCR analysis of OSM and VEGF mRNA levels. (H) 
RT-qPCR analysis of hCAP18/LL-37, OSM and VEGF mRNA levels in primary human monocyte-derived 
macrophages pre-treated for 1 h with a diluent control (Ctl), SB431542 (20µM) or SB505124 (20µM) and 
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subsequently cultured for 48h with control media, CSC CM, TGF-β1 (1ng/mL), or Nodal (300ng/mL) and 
Activin (100ng/mL). n.s. = not significant.  
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Figure 8: Targeting LL-37 receptors inhibit CSC phenotypes. (A) Diagram of the cross-talk between 
macrophages and CSCs, receptors and secreted factors involved, and specific inhibitors of these pathways. 
(B) RT-qPCR analysis of FPR2 and P2X7R mRNA levels in 3 primary PDAC cultures. (C) Flow cytometry 
analysis of P2X7R cell surface expression in 2 primary PDAC lines cultured as adherent or sphere cultures 
and treated with rLL-37. Percentage of CD133-positive cells within the P2X7R-positive subpopulation is 
shown in the right panels. (D and E) LL-37-treated sphere-derived PDAC cells were pre-treated with diluent 
control or WR-W4, KN-62 or a combination of both and (D) colony formation on Matrigel™, (E) invasion 
through MatrigelTM following stimulation with SDF-1 (+Ctrl = 20% FBS; –Ctrl = media alone) or (F) the 
percentage of CD133-positive cells measured by flow cytometry was determined.  
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Figure 9: Targeting LL-37 receptors inhibit PDAC development in vivo. (A) Experimental setup for in vivo 
short-term and long-term treatment. (B) Analysis of serum CTCs (RFP+). Representative flow cytometry 
plots are shown (left) and quantification of the frequency of circulating tumour cells/lineage negative cells 
following 5 weeks of treatment are shown (right) (n=4 mice/group).  (C) Representative images of mouse 
pancreata from control (n=4 mice) vs. treated (n=4 mice) KPC mice after 5 weeks of treatment (left). 
Quantitative analysis of PanIN/PDAC frequency and grading (right). n.s. = not significant. (D) Analysis of 
serum CTCs (EPCAM+). Representative flow cytometry plots are shown (left) and quantification of the 
frequency of circulating tumour cells/lineage negative cells following 16 weeks of treatment are shown 
(right) (n=4 mice/group).  (E) Representative images of mouse pancreata from control (n=4 mice) vs. 
treated (n=4 mice) KPC mice after 16 weeks of treatment (left). Quantitative analysis of PanIN/PDAC 
frequency and grading (right).  
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